PRURIGO NODULARIS

This phase 2 trial is testing whether a 5% cannabidiol (CBD) cream can reduce itching and skin severity in adults with chronic eczema conditions like atopic dermatitis and nummular eczema. About 60 participants will apply the CBD cream or a standard steroid cream for 4 weeks. The…

This study follows adults with moderate-to-severe prurigo nodularis—a skin condition marked by intensely itchy nodules—who are starting treatment with dupilumab (Dupixent) as part of their normal care. Researchers will track how well the drug reduces itching and clears skin lesio…

This phase 3 trial tests an oral drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and bumpy skin lesions. Participants receive either the drug or a placebo for 24 weeks. The study measures whether the drug reduces itch severity an…

This study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab…

This phase 2 trial tests a drug called barzolvolimab in 140 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug reduces itch severit…

This phase 3 trial tests an oral drug called povorcitinib in 349 adults with prurigo nodularis, a condition causing intense itching and hard skin bumps. Participants receive either the drug or a placebo for 24 weeks. The goal is to see if the drug reduces itch and clears skin les…

This study looks at the long-term safety of nemolizumab in 500 adults with prurigo nodularis, a condition causing severe itching and skin bumps. Participants must have taken nemolizumab in a previous study. The main goal is to track side effects over time, while also checking if …